Efficacy of an ultrashort-acting beta-adrenoceptor blocker (ONO-1101) in attenuating cardiovascular responses to endotracheal intubation

Objective: To investigate the clinical effectiveness and safety of ONO-1101, a new ultrashort-acting (half-life 3–4 min), cardioselective β-adrenoceptor blocker in attenuating the cardiovascular responses to endotracheal intubation in a dose-finding open study.